Stock LUPIN LUPIN LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lupin Limited

Equities

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 03:30:51 13/06/2024 pm IST 		5-day change 1st Jan Change
1,605 INR -0.00% Intraday chart for Lupin Limited -0.14% +21.34%
05/06 Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada MT
30/05 India's pharma export sales to grow faster this year, trade body says RE

Valuation

Fiscal Period: Marzo 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,34,438 2,67,133 4,63,185 3,39,061 2,94,760 7,31,858 - -
Enterprise Value (EV) 1 3,79,293 2,85,450 4,76,416 3,66,521 3,24,269 7,37,220 7,30,349 7,06,112
P/E ratio 55.3 x -99.1 x 38.2 x -22.2 x 68.8 x 38.6 x 30.4 x 25.2 x
Yield 0.68% 1.02% 0.64% 0.54% 0.62% 0.45% 0.53% 0.59%
Capitalization / Revenue 2 x 1.74 x 3.05 x 2.07 x 1.77 x 3.68 x 3.38 x 3.06 x
EV / Revenue 2.27 x 1.86 x 3.14 x 2.23 x 1.95 x 3.68 x 3.37 x 2.96 x
EV / EBITDA 13.2 x 12.1 x 18.6 x 16.9 x 18.8 x 19.4 x 16.7 x 14.1 x
EV / FCF 55.7 x 35.9 x 41.6 x -68.2 x 81.6 x 58 x 37.7 x 29 x
FCF Yield 1.79% 2.79% 2.4% -1.47% 1.23% 1.73% 2.66% 3.45%
Price to Book 2.44 x 2.13 x 3.36 x 2.79 x 2.36 x 5.18 x 4.49 x 3.92 x
Nbr of stocks (in thousands) 4,52,494 4,52,998 4,53,680 4,54,475 4,54,981 4,55,872 - -
Reference price 2 739.1 589.7 1,021 746.0 647.8 1,605 1,605 1,605
Announcement Date 15/05/19 28/05/20 12/05/21 18/05/22 09/05/23 06/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,67,182 1,53,748 1,51,630 1,64,055 1,66,417 2,00,108 2,16,792 2,38,884
EBITDA 1 28,822 23,548 25,669 21,656 17,206 38,000 43,642 50,221
EBIT 1 25,252 13,846 16,795 5,069 8,399 26,032 32,449 38,391
Operating Margin 15.1% 9.01% 11.08% 3.09% 5.05% 13.01% 14.97% 16.07%
Earnings before Tax (EBT) 1 15,172 7,572 16,764 -13,726 7,165 24,223 31,388 37,907
Net income 1 6,066 -2,694 12,165 -15,280 4,301 19,145 24,091 29,013
Net margin 3.63% -1.75% 8.02% -9.31% 2.58% 9.57% 11.11% 12.15%
EPS 2 13.36 -5.950 26.72 -33.65 9.410 41.87 52.82 63.63
Free Cash Flow 1 6,806 7,957 11,441 -5,378 3,974 13,058 19,391 24,390
FCF margin 4.07% 5.18% 7.55% -3.28% 2.39% 6.57% 8.94% 10.21%
FCF Conversion (EBITDA) 23.61% 33.79% 44.57% - 23.09% 35.86% 44.43% 48.57%
FCF Conversion (Net income) 112.21% - 94.05% - 92.39% 65.8% 80.49% 84.06%
Dividend per Share 2 5.000 6.000 6.500 4.000 4.000 7.151 8.540 9.547
Announcement Date 15/05/19 28/05/20 12/05/21 18/05/22 09/05/23 06/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 40,174 37,831 42,702 40,913 41,609 38,830 37,438 41,455 43,222 44,301 48,141 48,189 48,810 50,871 51,075
EBITDA 1 7,787 7,076 9,647 5,557 3,698 2,666 1,639 4,342 5,160 6,040 8,565 8,076 8,705 9,950 9,404
EBIT 1 5,344 4,918 7,560 -3,636 1,664 -605.4 -288.9 2,307 2,956 3,401 6,218 5,627 5,621 7,472 7,084
Operating Margin 13.3% 13% 17.7% -8.89% 4% -1.56% -0.77% 5.57% 6.84% 7.68% 12.92% 11.68% 11.52% 14.69% 13.87%
Earnings before Tax (EBT) 1 5,248 5,184 7,505 -22,048 1,671 -851.6 22.7 2,096 2,461 2,585 5,588 5,462 5,626 6,435 6,672
Net income 1 4,382 4,604 5,425 -20,980 5,455 -5,180 -890.8 1,297 1,535 2,360 4,523 3,969 4,436 5,229 4,916
Net margin 10.91% 12.17% 12.7% -51.28% 13.11% -13.34% -2.38% 3.13% 3.55% 5.33% 9.39% 8.24% 9.09% 10.28% 9.63%
EPS 2 9.700 10.11 11.91 -46.22 11.98 -11.40 -1.960 2.850 3.360 5.160 9.900 8.267 9.445 10.42 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 28/01/21 12/05/21 10/08/21 27/10/21 03/02/22 18/05/22 03/08/22 09/11/22 09/02/23 09/05/23 03/08/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 44,855 18,317 13,231 27,460 29,509 24,899 - -
Net Cash position 1 - - - - - - 1,508 25,745
Leverage (Debt/EBITDA) 1.556 x 0.7779 x 0.5155 x 1.268 x 1.715 x 0.6838 x - -
Free Cash Flow 1 6,806 7,957 11,441 -5,378 3,974 13,058 19,391 24,390
ROE (net income / shareholders' equity) 4.44% 2.68% 9.24% -11.8% 3.49% 14.3% 15.6% 16.4%
ROA (Net income/ Total Assets) 2.24% 1.33% 5.01% -6.73% 1.92% 8.38% 9.98% 11.3%
Assets 1 2,71,278 -2,02,214 2,42,971 2,27,157 2,23,883 2,36,905 2,41,383 2,57,485
Book Value Per Share 2 303.0 277.0 304.0 267.0 274.0 310.0 358.0 410.0
Cash Flow per Share 2 36.70 32.40 40.00 8.080 41.50 51.20 49.80 69.70
Capex 1 9,854 6,731 6,776 9,051 14,996 8,195 9,568 9,595
Capex / Sales 5.89% 4.38% 4.47% 5.52% 9.01% 4.12% 4.41% 4.02%
Announcement Date 15/05/19 28/05/20 12/05/21 18/05/22 09/05/23 06/05/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Lupin Limited

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
1,605 INR
Average target price
1,581 INR
Spread / Average Target
-1.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LUPIN LIMITED Stock Lupin Limited
+21.34% 876.98Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.79% 78TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.76% 64TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.43% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+7.18% 29TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.42% 25TCr
ROCHE HOLDING AG Stock Roche Holding AG
0.00% 22TCr
NOVARTIS AG Stock Novartis AG
+11.43% 22TCr
AMGEN INC. Stock Amgen Inc.
+4.53% 16TCr
PFIZER, INC. Stock Pfizer, Inc.
-3.92% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LUPIN Stock
  4. Financials Lupin Limited